Identification of CXCR4 Upregulation in Diffuse Large B-Cell Lymphoma Associated with Prognostic Significance and Clinicopathological Characteristics

Table 3

Cell viability of OCI-Ly3 and SU-DHL4 treated with WZ811.

WZ811 concentration (μM)		Cell viability %
OCI-Ly3	0 (group 1)	100	100	100
	10 (group 2)	79.99	86.18	83.95
	20 (group 3)	77.87	76.81	72.07
	40 (group 4)	68.54	68.69	70.56
	80 (group 5)	67.45	67.62	66.15
SU-DHL4	0 (group 6)	100	100	100
	10 (group 7)	98.75	91.94	98.8
	20 (group 8)	83.47	88.53	84.29
	40 (group 9)	73.31	78.82	75.12
	80 (group 10)	61.4	63.52	68.27